Search
Publication
Hepatitis B - Annual Epidemiological Report for 2019
For 2019, 30 EU/EEA Member States reported 29 996 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases, 29 518, corresponds to a crude rate of 7.4 cases per 100 000 population.
Publication
Hepatitis C - Annual Epidemiological Report for 2019
In 2019, 37 733 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases leaves 37 660 cases, which corresponds to a crude rate of 8.9 cases per 100 000 population.
Publication
The sustainable development goals and hepatitis B and C in the EU/EEA
In order to monitor progress towards the United Nations Sustainable Development Goals 2030 target to combat viral hepatitis, this report provides data on hepatitis B and C prevention, incidence, diagnosis, treatment, cure/viral suppression, and mortality in European Union/European Economic Area (EU/EEA) countries with data collected in 2019.
Publication
Hepatitis B and C testing in the EU/EEA: progress in reaching the elimination targets
This brief will present a snapshot of hepatitis B and C testing in the European Union/European Economic Area (EU/EEA), discussing progress made towards the European action plan 2020 testing target, focussing on key populations and settings for testing, barriers to testing, and testing policies.
Data
Surveillance systems overview for 2019
This spreadsheet contains all surveillance system overview tables from ECDC's annual epidemiological report for 2019.
- Anthrax
- Botulism
- Campylobacteriosis
- Chikungunya virus disease
- Chlamydia infection
- Cholera
- Crimean-Congo haemorrhagic fever
- Cryptosporidiosis
- Dengue
- Diphtheria
- Ebola haemorrhagic fever
- Echinococcosis
- EU/EEA
- Giardiasis
- Hantavirus infection
- Healthcare-associated infections
- Hepatitis A
- Hepatitis B
- Hepatitis C
- HIV infection
- Influenza
- Invasive Haemophilus influenzae disease
- Lassa fever
- Leptospirosis
- Listeriosis
- Malaria
- Marburg haemorrhagic fever
- Meningococcal disease
- Mumps
- Pertussis
- Plague
- Pneumococcal disease
- Poliomyelitis
- Q fever
- Rabies
- Rift Valley fever
- Salmonellosis
- Severe acute respiratory syndrome (SARS)
- Shigellosis
- Smallpox
- Surveillance
- Verotoxigenic Escherichia coli infection
- West Nile virus infection
Strengthening screening for infectious diseases and vaccination among migrants in Europe: What is needed to close the implementation gaps?
Peer-Reviewed Publication
Noori, T., Hargreaves, S., Greenaway, C., van der Werf, M., Driedger, M., Morton, R.L., Hui, C., Requena-Mendez, A., Agbata, E., Myran, D.T., Pareek, M., Campos-Matos, I., Nielsen, R.T., Semenza, J., Nellums, L.B., Pottie, K.
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines
Peer-Reviewed Publication
Sturkenboom, M., Bahri, P., Chiucchiuini, A., Grove Krause, T., Hahné, S., Khromava, A., Kokki, M., Kramarz, P., Kurz, X., Larson, H.J., de Lusignan, S., Mahy, P., Torcel-Pagnon, L., Titievsky, L., Bauchau, V.
Publication
Prevention of hepatitis B and C in the EU/EEA and the UK
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries
Peer-Reviewed Publication
Maticic, M., Pirnat, Z., Leicht, A., Zimmermann, R., Windelinck, T., Jauffret-Roustide, M., Duffell, E., Tammi, T., Schatz, E.
Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action
Peer-Reviewed Publication
Nakitanda, A.O., Montanari, L., Tavoschi, L., Mozalevskis, A., Duffell, E.